Urovant Sciences Ltd.
UROV
UROV was delisted on the 26th of March, 2021.
25 hedge funds and large institutions have $112M invested in Urovant Sciences Ltd. in 2019 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 9 closing their positions.
75% more capital invested
Capital invested by funds: $64.3M → $112M (+$48.2M)
7% less funds holding
Funds holding: 27 → 25 (-2)
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$10.8M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.93M |
| 3 |
PA
Perceptive Advisors
New York
|
+$1.74M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$287K |
| 5 |
Renaissance Technologies
New York
|
+$133K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.09M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
-$972K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$474K |
| 4 |
SCM
Sio Capital Management
New York
|
-$308K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$271K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PM
26
Prosight Management
Dallas,
Texas
| – | -$972K | -102,657 | Closed |
|
|
27
Point72 Asset Management
Stamford,
Connecticut
| – | -$474K | -50,000 | Closed |
|
28
Goldman Sachs
New York
| – | -$172K | -18,140 | Closed |
|
|
WMSA
29
Weiss Multi-Strategy Advisers
New York
| – | -$145K | -15,335 | Closed |
|
|
MWNA
30
Marshall Wace North America
New York
| – | -$24K | -2,567 | Closed |
|
31
Bank of America
Charlotte,
North Carolina
| – | -$14K | -1,463 | Closed |
|
|
CSS
32
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$12K | -1,239 | Closed |
|
33
Victory Capital Management
San Antonio,
Texas
| – | -$10K | -1,037 | Closed |
|
34
Barclays
London,
United Kingdom
| – | -$1K | -149 | Closed |
|
UROV Hedge Fund Activity: Q4 2019 in Review
25 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Urovant Sciences Ltd. (UROV) for Q4 2019, worth a combined $112M — up 75% from $64.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of UROV and 7 opened new positions — a net loss of 2 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $10.8M. The largest seller was Fidelity Investments, cutting an estimated $7.09M.
- 25 institutional investors held Urovant Sciences Ltd. (UROV) as of Q4 2019, down from 27 in Q3 2019.
- Funds reported $112M of Urovant Sciences Ltd. stock for Q4 2019, up 75% quarter-over-quarter.
- 7 funds opened new Urovant Sciences Ltd. positions in Q4 2019 and 9 closed out, a net change of -2 holders.
- The largest Urovant Sciences Ltd. buyer in Q4 2019 was Baker Bros. Advisors, an estimated $10.8M added.
- The largest Urovant Sciences Ltd. seller in Q4 2019 was Fidelity Investments, an estimated $7.09M sold.
Based on aggregated 13F filings for Q4 2019.